Form 4: Apellis Pharmaceuticals' Chief Scientific Officer Executes Stock Options and Sells Shares Under 10b5-1 Plan

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on March 8, 2024.

Summary

• On March 8, 2024, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options to acquire 69,107 shares of common stock at a price of $3.67 per share.
• Simultaneously, Deschatelets sold a total of 69,107 shares of Apellis common stock in four separate transactions.
• The sales were executed under a pre-arranged 10b5-1 trading plan established on December 8, 2023.
• The weighted average sale prices for the transactions ranged from $61.8754 to $63.35 per share.
• Following these transactions, Deschatelets directly owns 1,115,983 shares of Apellis Pharmaceuticals' common stock and 106,387 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, suggesting no immediate concern about the company's prospects, but the sale of shares could be perceived as slightly negative.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• While the sales are part of a pre-arranged plan, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

Insider transactions are common in publicly traded companies and are closely monitored by regulators and investors. The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the pharmaceutical industry like Regeneron, Vertex, and Amgen, to manage their stock holdings and avoid potential insider trading accusations.
• The size of the transaction is not unusual for an executive-level officer, and the weighted average sale prices are within the typical range for stock sales by insiders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for slight price fluctuations.

Key Dates